Neutralizing Antibody Response following a Third Dose of the mRNA-1273 Vaccine among Cancer Patients.
COVID-19
SARS-CoV-2
cancer patient
hematologic malignancy
lymphoid cancer
neutralizing antibody
vaccine
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
22 Dec 2023
22 Dec 2023
Historique:
received:
26
10
2023
revised:
06
12
2023
accepted:
19
12
2023
medline:
22
1
2024
pubmed:
22
1
2024
entrez:
22
1
2024
Statut:
epublish
Résumé
Cancer patients are at an increased risk of morbidity and mortality from SARS-CoV-2 infection and have a decreased immune response to vaccination. We conducted a study measuring both the neutralizing and total antibodies in cancer patients following a third dose of the mRNA-1273 COVID-19 vaccine. Immune responses were measured with an enzyme-linked immunosorbent assay (ELISA) and neutralization assays. Kruskal-Wallis tests were used to evaluate the association between patient characteristics and neutralization geometric mean titers (GMTs), and paired
Identifiants
pubmed: 38250826
pii: vaccines12010013
doi: 10.3390/vaccines12010013
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Moderna, Inc
ID : n/a